Kate A. Shanaghan

2 weeks ago | rheumatologyadvisor.com | Kate A. Shanaghan

Stacy Courtnay was diagnosed with rheumatoid arthritis (RA) when she was just 24 years old, shortly after marrying her now husband. Her symptoms, which originated in her lower extremities, progressed quickly and became incapacitating. “I just felt like somebody was taking a hammer to my feet,” she explained. By the time she saw a rheumatologist, she was unable to perform simple daily tasks, such as lifting her shoulders, bringing a cup to her mouth, or even squeezing a tube of toothpaste.

Nov 20, 2024 | rheumatologyadvisor.com | Sophie Gao |Kate A. Shanaghan

Throughout 2024, the United States Food and Drug Administration (FDA) approved new drugs for the treatment of osteoporosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), giant cell arteritis, Duchenne muscular dystrophy (DMD), and certain cancers, while also expanding treatment indications for previously approved drugs. On March 5, 2024, the FDA approved Jubbonti, the first interchangeable biosimilar for Prolia® (denosumab).

Oct 4, 2024 | rheumatologyadvisor.com | Kate A. Shanaghan

The process of being diagnosed with an autoimmune disease is rarely linear. This proved especially true for Talisa King, who was diagnosed with rheumatoid arthritis (RA) when she was only 31 years of age. King, who was officially diagnosed with RA back in 2012, is an African American woman living in Buffalo, New York. Prior to her diagnosis, she was not symptomatic.

Jul 16, 2024 | thecardiologyadvisor.com | Kate A. Shanaghan

Mortality rates are high among patients with rheumatic heart disease (RHD) and are associated with valve disease severity at diagnosis, according to study results published in JAMA. Annually, over 300,000 deaths are attributed to RHD, particularly among patients in low- and middle-income countries. Updated and globally-representative morbidity and mortality data on persons living with RHD are lacking.

Jun 21, 2024 | rheumatologyadvisor.com | Kate A. Shanaghan

Mortality rates are high among patients with rheumatic heart disease (RHD) and are associated with valve disease severity at diagnosis, according to study results published in JAMA. Annually, over 300,000 deaths are attributed to RHD, particularly among patients in low- and middle-income countries. Updated and globally-representative morbidity and mortality data on persons living with RHD are lacking.